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Abstract Genetic variants of paraoxonase 1 (PON1) were
implicated in stroke susceptibility in several case–control
association studies. However, the studies have reported
apparently conflicting results, rendering precise assessment
of the disease risk associated with the variants difficult. A
meta-analysis was therefore conducted by including the
studies that examined the association between two common
polymorphisms (L55M and Q192R) in the coding region of
PON1 gene and the risk of stroke. Altogether 10 studies on
L55M polymorphism and 11 studies on Q192R polymor-
phism were included in this meta-analysis. The results
showed, although there was no significant association of the
55L allele with stroke [random effects OR = 1.09, 95% CI
(0.93, 1.27), P = 0.29], the 192R allele conferred significant
risk of stroke in the overall study population [random effects
OR = 1.25, 95% CI (1.07, 1.46), P = 0.006]. Same pattern
of results as both the allele contrasts was obtained for the
homozygote contrasts and the dominant, recessive and
additive models. Subgroup analyses for stroke type, age of
patients and ethnicity revealed no association of the 55L
allele with stroke, whereas the association of the 192R allele
persisted significantly in the groups comprising ischemic
stroke patients, stroke patients with mean age[60 years and
Caucasian subjects. But no significant association of this
allele with stroke susceptibility was detected in the East
Asian population. Therefore, the results of this meta-analysis
indicate, the Q192R polymorphism could be an important
risk factor for stroke, especially in the Caucasian population.
Keywords Paraoxonase 1  Polymorphism  Stroke 
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Introduction
Stroke is a heterogeneous multifactorial disorder that
accounts for the largest number of mortality in the world
after heart attack and cancer [1]. It is also the leading cause
of disability in the world, placing heavy burden on the
society [2]. Although stroke could be caused by any or a
combination of the traditional risk factors such as hyper-
tension, diabetes, smoking, hyperlipidemia etc., growing
number of evidences suggest genetic factors play a crucial
role in stroke etiology through their interactions with the
environmental components [3]. It is, therefore, important to
identify the gene variants contributing to stroke patho-
genesis. The knowledge of the genetic factors influencing
stroke susceptibility could be instrumental in enhancing the
prediction of disease risk and devising efficient therapeutic
strategies, based on targeted approach.
Several genetic association studies have accumulated
evidence that a number of genes involved in cholesterol
metabolism, inflammation, blood coagulation, homocyste-
ine metabolism, rennin-angiotensin system etc. could be
implicated in the development of stroke [4]. Of these
genes, human serum paraoxonase 1 (PON1) stands as a
potential candidate. PON1 is a calcium-dependent glyco-
protein that is associated with high density lipoprotein
(HDL) in serum [5]. It preserves HDL functions and pre-
vents oxidation of the low density lipoproteins (LDL) by
hydrolyzing lipid peroxides [6, 7]. It also metabolizes the
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biologically active lipids in oxidized LDLs and thereby
prevents the induction of monocyte-endothelial interac-
tions on the arterial wall [8]. Therefore, the biological
functions of PON1 suggest its role against the pathogenesis
of atherosclerosis, the major underlying cause of ischemic
stroke and other cardiovascular diseases. In addition, the
findings that PON1 activity is lowered in vascular diseases
and PON1 knockout mice have increased susceptibility to
atherosclerosis have further supported the role of PON1 as
an antioxidant and antiatherogenic enzyme [6, 9, 10].
PON1 gene has two common single nucleotide poly-
morphisms (SNPs) in the coding region of the gene,
leading to Gln(Q) ? Arg(R) and Leu(L) ? Met(M) sub-
stitutions at positions 192 and 55, respectively. These two
variants have been shown to influence PON1 activity and
serum concentrations independently [11, 12]. Several
studies have shown both the Q192R (rs662) and L55M
(rs854560) polymorphisms are associated with increased
risk of coronary-artery disease (CAD), but there were
inconsistencies in the results as other studies failed to
detect any association [3]. Homozygosity for the 55L allele
was shown to confer risk to CAD independently, but the
subsequent studies demonstrated conflicting results [13].
Recent studies were also aimed to discern the role of these
SNPs in stroke, following the common mechanistic links
between stroke and CAD. But majority of the individual
studies were of low statistical power, due to which the
degree of association between the PON1 gene variants and
stroke could not be determined with reliability. Moreover,
ethnic influences on studies in different populations across
the world further obscured the true nature of association
between these gene variants and stroke.
In order to investigate the precise relationship between
the PON1 gene variants and stroke, a study with high
statistical power was necessary. Therefore, to quantify in a
reliable manner the genetic risks associated with the PON1
Q192R and L55M polymorphisms in stroke susceptibility,
a meta-analysis of all available published studies was
performed. In this meta-analysis, the overall association of
the gene variants with stroke was investigated. To examine
the possible influence of various factors like stroke-type,
age and ethnicity on the overall results, subgroup analyses
were also conducted. The subgroups were comprised of the
studies on ischemic stroke, patients with mean age more
than 60 years, East Asian and Caucasian populations.
Materials and methods
Study identification and selection of relevant studies
A literature search of the PubMed database was conducted
to identify all articles that examined the association of the
PON1 gene variants with stroke. The terms ‘‘stroke’’,
‘‘paraoxonase1’’, ‘‘PON1’’ and ‘‘polymorphism’’ were used
as search criteria. Articles reporting the association of the
PON1 Q192R and L55M polymorphisms with stroke were
identified. All the studies that were published before June,
2008 were considered for initial screening. The articles
written in English were considered only. The search results
were limited to humans.
To assess the appropriateness of the studies for inclusion
in this meta-analysis, the publications were read in their
entirety. Abstracts, editorials and review articles were
excluded. Clinically overt case–control studies included in
this meta-analysis had to meet all of the following criteria:
(a) stroke was diagnosed by neurologists as neurological
deficits with characteristic symptoms, accompanied by
abnormal brain lesions as evident in either magnetic reso-
nance imaging (MRI) or computed tomography (CT), and
patients with other cerebrovascular diseases were excluded,
based on the reports of MRI or CT and other diagnostic
tests, (b) control subjects were unrelated individuals, cho-
sen randomly from the same geographic region, and
without any symptomatic vascular disease as confirmed by
physicians after physical examination and by evaluating
clinical history and diagnostic tests, (c) cases with transient
ischemic attack (TIA) or cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencepha-
lopathy (CADASIL) were excluded, and (d) genotype
distributions in both cases and controls were available.
Data extraction
The following information were extracted from each study:
name of the first author, year of publication, country,
journal, racial descent of study population, demographics,
number of cases and controls, genotyping methods, geno-
type and allele distributions and confirmation of diagnosis.
If allele frequencies were not given, they were calculated
from the corresponding genotype distributions.
Statistical analysis
For each variant of PON1, meta-analysis was performed to
examine the overall association for the allele contrast, the
contrast of homozygotes, and the recessive, dominant and
additive models.
To measure the strength of genetic association for each
gene variant, the odds ratios (ORs), together with the 95%
confidence interval (CI) and the corresponding P value (the
P value being significant if \0.05) were calculated. Het-
erogeneity between the studies was examined by Q-statis-
tic, which is a weighted sum of squares of the deviations of
individual study OR estimates from the overall estimate,
[14]. Q follows a chi-square distribution with r - 1 (r is
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the number of studies) degrees of freedom (df), when the
ORs were homogeneous [15]. The heterogeneity was
considered statistically significant with P \ 0.10. Quantifi-
cation of the heterogeneity was done with the I2 metric
(I2 = (Q - df)/Q), which is independent of the number of
studies in the meta-analysis [16]. The I2 values falls within
the range 0–100%, with higher values denoting greater
degree of heterogeneity (I2 = 0–25%, no heterogeneity;
I2 = 25–50%, moderate heterogeneity; I2 = 50–75%, large
heterogeneity; I2 = 75–100%, extreme heterogeneity) [15].
The Mantel–Haenszel method was used to calculate the
fixed-effect pooled ORs [17, 18]. The random-effects pooled
ORs were calculated by the DerSimonian and Liard method
[19]. As the studies are both clinically and methodologically
diverse, heterogeneity between studies is an expected out-
come [20]. If heterogeneity existed between studies, a pooled
OR was estimated by the random-effects model, because this
model assumes a genuine diversity in the results of the
studies, incorporating the calculations of inter-study vari-
ability and provides wider CIs [15, 21]. In this article, the
results from the random-effects model are reported only. To
assess the publication bias for allele contrasts, the Egger
regression test for funnel plot asymmetry [15, 22, 23] and the
Begg–Mazumdar test, which is based on Kendall’s tau [24],
were carried out. To examine the effect of the studies with
controls that are not in Hardy–Weinberg equilibrium, sen-
sitivity analyses were performed by their exclusion [15].
Subgroup analyses of the studies on ischemic stroke, patients
with mean age[60 years, East Asian and Caucasian popu-
lations, were also carried out. The statistical software
StatsDirect (version 2.5.7) was used to analyze the data.
Results
Study inclusion
The initial search with the key words and subject terms
identified a total of 22 studies. Of these, based on the
searching criteria, thirteen articles were retrieved [25–37].
Due to unavailability of the article and the genotype data,
two studies were excluded [36, 37]. Finally, eleven studies
[25–35] were considered for the meta-analysis on the
Q192R and L55M variants of the PON1 gene. For sub-
group analyses, studies were stratified according to the
stroke type (ischemic stroke [25–31, 34, 35]), age (mean
age of the patients [60 years [25–28, 30, 31, 33, 35]) and
ethnicity (East Asian population [25, 29, 31, 33, 35] and
Caucasian population [26–28, 30, 32]). One study investi-
gated the association between the paraoxonase gene vari-
ants with different forms of stroke such as, small vessel
disease, large vessel disease, cardioembolic stroke [28].
However, for each subtype of stroke, different control
groups were included. To avoid complications for statisti-
cal analysis, only the data for the large vessel disease were
considered for this meta-analysis. One study was con-
ducted in a population of mixed ethnic background com-
prising subjects from Caucasian, African and Asian
populations [34]. Studies with controls not in Hardy–
Weinberg equilibrium (HWE) were also considered for the
meta-analysis, but they were excluded in the sensitivity
analysis.
In most of the studies included in this meta-analysis,
stroke cases were incidental, not prevalent. Genotype
determination in the included studies was carried out by
polymerase chain reaction-restriction fragment length
polymorphism (PCR–RFLP) method, except for two stud-
ies [25, 32] where other genotyping techniques were used.
To adjust the ORs for potential risk factors for vascular
diseases such as hypertension, smoking habit, diabetes etc.,
logistic regression analysis was performed in some of the
studies [26, 31, 32, 34].
Summary statistics
Characteristics of the included studies on PON1 L55M and
Q192R polymorphisms are shown in Table 1. The studies
provided 1,484 cases and 4,075 controls for L55M and
1,726 cases and 4,379 controls for Q192R. The genotype
distributions and the allele frequency of L55M and Q192R
are shown in Tables 2 and 3, respectively. Out of the 10
studies on L55M included in this meta-analysis, the control
group of one study did not follow HWE [30], and therefore,
was excluded in the sensitivity analyses. For Q192R, there
were altogether 11 studies included in this meta-analysis.
In the sensitivity analyses for this gene variant, 3 studies
were excluded where the control groups did not follow
HWE [25, 33, 34].
Main results, sensitivity and subgroup analyses
In the meta-analysis of PON1 L55M polymorphism
(Table 4; Fig. 1), the summary ORs showed no statistically
significant association of the L allele with the susceptibil-
ity to stroke as compared to the M allele under the
random effects model, OR = 1.09 [95% CI (0.93, 1.27)];
P = 0.29. No inter-study heterogeneity was observed for
this allelic variant (I2 = 20; P = 0.26). In the sensitivity
analysis, where the study with controls not in HWE was
excluded, no heterogeneity was observed (I2 = 14.6;
P = 0.31), and no association of the L allele with stroke
was found, the random effects OR = 1.05 [95% CI (0.90,
1.23)]; P = 0.51. The Begg-Mazumdar test, although
indicated low power for this meta-analysis, showed no
significant publication bias, Kendall’s tau = 0.29;
P = 0.29. The Egger’s test also showed no publication
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bias, P = 0.87. In the genotype contrasts LL vs. MM, LL
vs. LM vs. MM, LL vs. (LM ? MM), no statistically
significant association was detected, although some OR
values indicated high risk for stroke. The carriers of L
allele (genotypes LL ? LM) showed significant associa-
tion as compared to the MM homozygotes, the random
effects OR = 1.64 [95% CI (1.12, 2.41)]; P = 0.01.
However, in the sensitivity analysis this association
became non-significant, the random effects OR = 1.39
[95% CI (0.97, 1.99)]; P = 0.07.
The results on the Q192R polymorphism (Table 4 and
Fig. 2) indicated, the R allele could contribute significantly
to stroke susceptibility as compared to the Q allele, the
random effects OR = 1.25 [95% CI (1.07, 1.46)];
P = 0.006. No significant publication bias was found by
the Begg-Mazumdar test, Kendall’s tau = -0.05; P =
0.76. The Egger’s test also showed no significant publi-
cation bias P = 0.95. However, large heterogeneity among
the studies was observed (I2 = 59.3; P = 0.006). The
degree of heterogeneity was not altered much in the sen-
sitivity analysis (I2 = 60.2; P = 0.01). In the genotype
contrasts RR vs. QQ, RR vs. RQ vs. QQ, RR vs.
(RQ ? QQ) and (RR ? RQ) vs. QQ, statistically signifi-
cant associations were detected in all studies and in sen-
sitivity analyses, indicating both the RR genotype and the
R allele carriers are at high risk for stroke.
In the subgroup analyses (Table 5), no association
between the L55M polymorphism and stroke was revealed
in any of the groups analyzed. However, the Q192R
polymorphism was found to be significantly associated
with stroke susceptibility in the groups comprising Cau-
casian subjects, the random effects model, OR = 1.32
[95% CI (1.01, 1.71)]; P = 0.04, ischemic stroke patients,
the random effects model, OR = 1.21 [95% CI (1.02,
1.43)]; P = 0.03, and the patients with mean age
[60 years, the random effects model, OR = 1.20 [95% CI
(1.03, 1.41)]; P = 0.02. Moderate to large heterogeneity
persisted in all the groups for the Q192R polymorphism.
Interestingly, no significant association between the R
allele and stroke was detected in the East Asian population,
the random effects model, OR = 1.14 [95% CI (0.92,
1.42)]; P = 0.23.
Discussion
The first report evaluating the role of PON1 polymor-
phisms in the predisposition of ischemic stroke was pro-
duced by Imai et al. [35], where the R allele of Q192R
polymorphism was found to be an independent risk factor
for the disease in a Japanese population. The same study
also investigated the relationship between the L55M
polymorphism and ischemic stroke, but could not detect
any association. Previous studies demonstrated the L55M
and Q192R polymorphisms in the PON1 gene could
contribute to the risk of CAD, possibly through
Table 1 Characteristics of the studies of PON1 L55M and Q192R polymorphisms and stroke (M/F male/female)
Population Stroke type Case Control Polymorphisms Reference
East Asian Ischemic 350 patients (M/F = 1.3/1); mean
age 67.4 ± 11.3 years
242 controls (M/F = 1/1); mean
age 67.8 ± 8.4 years
L55M, Q192R [25]
Caucasian Ischemic 108 patients (77.8% male); mean
age 64.2 ± 15.3 years
78 controls (57.1% male); mean
age 63.2 ± 13.4 years
L55M, Q192R [26]
Caucasian Ischemic 126 patients (63.3% male); mean
age 66.0 years
92 controls (60.7% male); mean
age 65.0 years
L55M, Q192R [27]
Caucasian Ischemic 136 patients (M/F = 89/47); mean
age 65.8 ± 11.5 years
238 controls (M/F = 142/96);
mean age 66.0 ± 11.0 years
L55M, Q192R [28]
East Asian Ischemic 153 patients (M/F = 92/61); mean
age 59.8 ± 12.0 years
153 controls (M/F = 89/64); mean
age 57.7 ± 8.8 years
L55M, Q192R [29]
Caucasian Ischemic 65 patients (46.2% male); mean age
70.4 ± 11.9 years
84 controls (31% male); mean age
67.7 ± 3.9 years
L55M, Q192R [30]
East Asian Ischemic 242 patients (54.5% male); mean
age 70.7 ± 12.0 years
336 controls (45.2% male); mean
age 71.0 ± 5.9 years
Q192R [31]
Caucasian Ischemic and
hemorrhagic
81 patients (M/F = 69/12); mean
age 58.0 ± 9.3 years
2,553 controls (M/F = 2,216/337);
mean age 64.0 ± 7.5 years
L55M, Q192R [32]
East Asian Cerebral
infarction
112 patients (M/F = 69/46); mean
age 70.0 ± 9.9 years
106 controls (M/F = 48/58); mean
age 69.0 ± 9.6 years
L55M, Q192R [33]
Mixed (Caucasian,
African and Asian)
Ischemic 118 patients (45.8% male); mean
age 36.3 ± 6.6 years
118 controls (45.8% male); mean
age 36.6 ± 6.8 years
L55M, Q192R [34]
East Asian Ischemic 235 patients (M/F = 115/120);
mean age 69.5 ± 8.5 years
431 controls (M/F = 321/110);
mean age 63.6 ± 9.1 years
L55M, Q192R [35]
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exaggeration of atherosclerotic events [12, 38–40]. How-
ever, discordant results were also reported from studies in
different populations [41–44]. A meta-analysis on Q192R
polymorphism failed to show any strong evidence that the
polymorphism is associated with CAD risk in either
Caucasian men or women [45]. Another meta-analysis,
with higher number of studies included, demonstrated
there was no overall association of CAD with the L55M
Table 4 Summary of odds ratios (OR) with confidence intervals (CI) for various genetic contrasts of the PON1 L55M and Q192R polymor-
phisms for stroke patients
Genetic contrasts Populations Studies (n) Alleles/
Genotypes (n)
Random effects
[OR (95% CI)]
Random effects
P value
I2 (%) Q test
P value
L versus M All 10 11,118 1.09 (0.93, 1.27) 0.29 20.0 0.26
All in HWE 9 10,820 1.05 (0.90, 1.23) 0.51 14.6 0.31
R versus Q All 11 12,210 1.25 (1.07, 1.46) 0.006 59.3 0.006
All in HWE 8 10,118 1.28 (1.06, 1.54) 0.01 60.2 0.01
LL versus MM All 8 2,782 1.40 (0.98, 1.99) 0.06 0 0.69
All in HWE 7 2,704 1.34 (0.92, 1.95) 0.13 0 0.64
RR versus QQ All 10 3,206 1.78 (1.23, 2.57) 0.002 55.5 0.02
All in HWE 8 2,954 1.72 (1.14, 2.58) 0.01 56.2 0.02
LL versus LM versus MM All 10 5,559 1.09 (0.90, 1.33) 0.37 0 0.74
All in HWE 9 5,410 1.06 (0.87, 1.30) 0.56 0 0.75
RR versus RQ versus QQ All 11 6,105 1.25 (1.07, 1.46) 0.005 18 0.27
All in HWE 8 5,059 1.29 (1.07, 1.55) 0.007 20.2 0.27
LL versus (LM ? MM) All 10 5,559 0.97 (0.82, 1.16) 0.78 0 0.52
All in HWE 9 5,410 0.99 (0.83, 1.18) 0.91 0 0.47
RR versus (RQ ? QQ) All 10 5,513 1.32 (1.06, 1.66) 0.01 32.1 0.15
All in HWE 8 5,059 1.28 (1.04, 1.59) 0.02 18.0 0.29
(LL ? LM) versus MM All 8 4,661 1.64 (1.12, 2.41) 0.01 22.7 0.25
All in HWE 7 4,512 1.39 (0.97, 1.99) 0.07 0 0.59
(RR ? RQ) versus QQ All 11 6,105 1.40 (1.05, 1.87) 0.02 69.4 0.0003
All in HWE 8 5,059 1.50 (1.03, 2.19) 0.04 73.1 0.0005
HWE Hardy–Weinberg equilibrium
0.1 0.2 0.5 1 2 5 10
All 1.09 (0.93, 1.27)
Caucasian Population 1.12 (0.95, 1.33)
East Asian Population 0.97 (0.57, 1.67)
Imai, 2000 1.08 (0.69, 1.72)
Voetsch, 2002 1.02 (0.68, 1.53)
Ueno, 2003 0.36 (0.13, 0.86)
Ranade, 2005 1.11 (0.79, 1.57)
Aydin, 2006 1.48 (0.91, 2.41)
Huang, 2006 2.03 (0.62, 7.67)
Slowik, 2007 0.99 (0.72, 1.38)
Schiavon, 2007 0.99 (0.65, 1.53)
Can Demirdogen, 2008 1.32 (0.83, 2.07)
Shin, 2008 1.19 (0.68, 2.08)
Odds ratio (95% confidence interval)
Fig. 1 Results of the published
studies of the association
between PON1 L55M
polymorphism and stroke in the
East Asian, Caucasian and
combined populations. Each
study is shown by an OR
estimating the outcome of the
comparison of the L allele
against the M allele with the
corresponding 95% CI. The
random effects pooled ORs are
shown. The size of the box is
proportional to the weight of the
study
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polymorphism, whereas weak association was detected
with the Q192R polymorphism, which was of uncertain
relevance as there was no significant association among
the larger studies [46]. Since there may be common risk
traits for both CAD and stroke, studies were also initiated
to test the associations between paraoxonase gene poly-
morphisms and stroke, assuming they could lead to both
the disorders through their participation in systemic ath-
erogenesis [35, 47]. A number of studies investigating the
role of PON1 polymorphisms in stroke susceptibility
followed the study of Imai et al. But the studies yielded
apparently conflicting results.
There could be several factors contributing to discordant
findings among individual studies. Small sample size is one
of them, which often enhances the chance factor for false-
positive or false-negative findings. In meta-analysis, how-
ever, the false-positive and false-negative results neutralize
each others as large number of studies is pooled, and the
increase of overall statistical power leads to a more precise
and accurate measure of association. Variation among
results of different studies might also be the consequence
of different sampling strategies and/or ethnical variation
among the study populations. If considerable number of
reports are available on ethnically distinct populations,
separate meta-analysis on each of the major population
groups might provide significant insight on the cause of
discordant results.
To help clarify the evidences from different studies, a
meta-analysis was performed on the data pooled from the
available published studies examining the association
between PON1 polymorphisms and stroke. The relation-
ship between stroke and the L55M and Q192R polymor-
phisms in the coding region of PON1 gene was
investigated. The overall results suggest, although the 55L
0.5 1 2 5
All 1.25 (1.07, 1.46)
Caucasian Population 1.32 (1.02, 1.71)
East Asian Population 1.14 (0.92, 1.42)
Imai, 2000 1.61 (1.24, 2.09)
Voetsch, 2002 1.64 (1.10, 2.43)
Ueno, 2003 1.11 (0.74, 1.67)
Ranade, 2005 1.82 (1.30, 2.53)
Baum, 2006 1.23 (0.96, 1.58)
Aydin, 2006 1.77 (1.08, 2.92)
Huang, 2006 0.88 (0.63, 1.24)
Slowik, 2007 1.18 (0.83, 1.67)
Schiavon, 2007 0.96 (0.63, 1.47)
Can Demirdogen, 2008 1.07 (0.68, 1.68)
Shin, 2008 0.95 (0.73, 1.24)
Odds ratio (95% confidence interval)
Fig. 2 Results of the published
studies of the association
between PON1 Q192R
polymorphism and stroke in the
East Asian, Caucasian and
combined populations. Each
study is shown by an OR
estimating the outcome of the
comparison of the R allele
against the Q allele with the
corresponding 95% CI. The
random effects pooled ORs are
shown. The size of the box is
proportional to the weight
of the study
Table 5 Subgroup analyses for allele contrasts of the PON1 L55M and Q192R polymorphisms for stroke patients
Subgroups Allelic
contrasts
Studies (n) Alleles (n) Random effects
[OR (95% CI)]
Random effects
P value
I2 (%) Q test
P value
East Asian population L vs. M 4 3,564 0.97 (0.57, 1.67) 0.93 62.5 0.04
R vs. Q 5 4,668 1.14 (0.92, 1.42) 0.23 65.9 0.02
Caucasian population L vs. M 5 7,082 1.12 (0.95, 1.33) 0.17 0 0.6
R vs. Q 5 7,070 1.32 (1.01, 1.71) 0.04 56.1 0.06
Ischemic stroke L vs. M 8 5,450 1.12 (0.96, 1.31) 0.13 0 0.7
R vs. Q 9 6,558 1.21 (1.02, 1.43) 0.03 56.8 0.02
Mean age of patients [60 years L vs. M 7 4,802 1.07 (0.86, 1.33) 0.54 39.1 0.13
R vs. Q 8 5,910 1.20 (1.03, 1.41) 0.02 44.6 0.08
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allele did not show any association with stroke, the 192R
allele could confer risk to stroke susceptibility signifi-
cantly. The results remained unaffected in the sensitivity
analysis where studies with controls not in Hardy–Wein-
berg equilibrium were excluded, indicating reliability and
stability of the results. Subgroup analyses taking into
account patient characteristics and ethnicity failed to
identify any association between the 55L allele and stroke
susceptibility, but significant association of the 192R allele
with stroke risk was revealed in the groups comprising the
patients with ischemic stroke, the patients with mean age
more than 60 years and the subjects from the Caucasian
population, but not from the East Asian population.
In the retrospective cumulative meta-analysis of the
studies on L55M polymorphism (data not shown), the
random effects OR of the allelic contrast was found to
decrease from 1.08 (first study in 2000) to 0.83 (three
studies in 2003). After that the OR showed an increasing
trend: 1.07 (six studies in 2006) to 1.09 (ten studies in
2008), even though the association remained non-signifi-
cant throughout. However, the random effects OR for the
Q192R polymorphism showed a decreasing trend from
1.61 (first study in 2000) through 1.47 (three studies in
2003) and 1.38 (seven studies in 2006) to 1.25 (eleven
studies in 2008), despite the fact that the association
remained statistically significant each time.
As the publication of findings often depends on the
expectation of researchers, false-negative results may be
suppressed or false-positive results magnified [48, 49]. The
results of this study, however, did not show any significant
publication bias. However, since the number of studies
included in this meta-analysis was small and large inter-
study heterogeneity was observed, these results should be
considered with caution. The possibility that the results
were affected by false-positive or false-negative findings
could not be ruled out. In this meta-analysis, although there
was no heterogeneity among the studies on the L55M
polymorphism, large heterogeneity was observed among
the studies on the Q192R polymorphism, which did not
alter much in the sensitivity analysis. The observed heter-
ogeneity could be attributable to differences in several
factors such as ethnic variations, environmental factors and
methodological factors in design and conduct of the stud-
ies. Among these factors, ethnicity could play a crucial role
as the allele frequencies of the L55M and Q192R poly-
morphisms were found to vary between the East Asian and
the Caucasian populations: the frequency of the L allele in
the East Asian population was 94% in controls and 95%
in cases, whereas, in the Caucasian population it was 63%
in controls and 65% in cases. The R allele frequency in the
East Asian population was 55% in controls and 54% in
cases, whereas in the Caucasians, the frequency was 24%
in controls and 35% in cases. An earlier study also revealed
very distinctive distribution of the allele frequencies of the
192R and the 55M alleles for the Caucasian, Asian
and Afro-American populations [50]. In this study, the
observed positive association of the 192R allele with stroke
susceptibility in the Caucasian population, and the lack of
association in the East Asian population suggest that eth-
nicity could be a potential determinant of the disease risk,
owing to the differences in genetic architecture of these
two populations.
It is also important to note that a linkage disequilib-
rium (LD) exists between the 192R and the 55L alleles
[51]. A study in the Caucasian population found, nearly
all of the 192R alleles encode 55L and the 192R/55M
genotype was very rare [52]. However, in a population of
African descent, this LD appeared to be less extreme [51].
A comparative study revealed, the Euro-Brazilians with
192RR genotype lacked the 55M allele, whereas the same
was present in a group of Afro-Brazilians [50]. The high
LD, observed in this study, in the Caucasian and in the
Asian populations was mainly due to the absence or very low
frequency of the MR haplotype [50]. The LD existing
between these two polymorphisms may be in part responsi-
ble for the previously reported relationship between the 55L
variant and the risk of stroke, which is not evident in this
study.
This study has some limitations that need to be
acknowledged. First, the number of available studies that
could be included in this meta-analysis was moderate.
Therefore, the results could be influenced by the factors
like random error, publication bias etc. Second, the case–
control association studies included in this meta-analysis
were small or medium-sized, with little statistical power to
reliably assess the relevance of the SNPs to the risk of
stroke. Third, this study could not address gene–gene and
gene-environment interactions. Fourth, variation in clinical
classification of stroke patients and controls, genotyping
and ethnic polymorphy among the included studies could
influence the overall outcome of this meta-analysis. Fifth,
since the number of studies included in the subgroup
analyses was small, the results, although indicative, lack
sufficient reliability to confirm or refute an association in a
definitive manner.
In conclusion, the results of this meta-analysis suggest
the PON1 L55M polymorphism is not associated with the
susceptibility to stroke in the study populations. However,
the Q192R polymorphism of the same gene could be
regarded as a potential risk factor for stroke, especially in
the Caucasian population.
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